Goodland Pharma

A recent review explored 2 different breakthrough therapies for Multiple Myeloma: CAR-T and BsAbs. ✳️ The landscape of multiple myeloma (MM) treatment has undergone a remarkable evolution, with novel agents revolutionising therapeutic strategies. Among these, B-cell maturation antigen (BCMA) has emerged as a promising target, leading to the development of innovative immune approaches. ✳️ Immunotherapies leveraging chimeric antigen receptor (CAR)-engineered T-cells and bispecific antibodies (BsAbs) have garnered significant attention in MM treatment, demonstrating superior potential over conventional regimens. Recent clinical trials underscore their efficacy, positioning them as pivotal players in MM management. ✳️ However, while CAR-T and BsAbs targeting BCMA offer breakthrough potential, their integration into clinical practice presents challenges. This review delves into associated limitations, emphasising the importance of patient selection and treatment customisation. Optimising efficacy and minimising toxicity through strategic combination or sequencing of therapies is paramount, particularly for patients with limited treatment options. Read the full review here: https://bit.ly/3wRO5ha #MultipleMyeloma #Immunotherapy #CAR-T #BsAbs

At Goodland Pharma, our expertise is not just broad; it's deeply specialised in the pivotal areas that drive the success of clinical trials worldwide. With a laser focus on Clinical Operations, Regulatory Affairs, and Quality Assurance, we're dedicated to providing unmatched support and talent solutions tailored to your precise needs. We're equipped to meet your recruitment needs with precision and efficiency, helping you achieve your goals with confidence. Get started here: https://lnkd.in/g_z8FmWD #GoodlandPharma #RecruitmentPartnership #ClinicalTrials #LifeScience

New study highlights benefits of CRT-D in non-ischemic cardiomyopathy patients! Cardiac resynchronisation therapy (CRT) has long been heralded as a breakthrough for heart failure patients with electrical desynchrony. A recent meta-analysis comparing CRT with implantable cardioverter-defibrillator (CRT-D) to CRT with pacemaker only (CRT-P) in non-ischemic cardiomyopathy (NICM) patients sheds light on its efficacy. The study, pooling data from 13 studies and over 61,000 patients, found that CRT-D significantly lowers the risk of all-cause mortality compared to CRT-P (pooled HR 0.74; 95% CI: 0.62-0.88). However, this benefit was not observed in patients older than 75 years. While CRT-D didn't show a significant reduction in cardiovascular mortality, its impact on overall survival underscores its importance in managing NICM. More details from the full article here: https://bit.ly/3yzELz4 #HeartFailure #CRTTherapy #Defibrillator #Cardiomyopathy

We believe in leveraging our expertise and resources to contribute meaningfully to the advancement of healthcare. At the end of the day, our success is measured by the positive impact we have on others. Trust us to be your ally in realising your goals and making a difference where it matters most. Check out our website for more: https://lnkd.in/g_z8FmWD #GoodlandPharma #LifeScience #ClinicalTrials #RecruitmentPartnership

A recent study discussed in Applied Clinical Trials sheds light on the influence of assigned roles on patient-reported outcomes (PROs) in clinical trials. Here are the key insights: 💡 Role Assignment Dynamics: The study delves into how patients' assigned roles within clinical trials can significantly impact their reported outcomes. This highlights the importance of considering not just treatment efficacy but also the psychosocial factors associated with different trial roles. 💡Patient Perception: Patients' perceptions of their roles, whether as active participants or controls, can influence their engagement and subsequent reporting of outcomes. Understanding these dynamics is crucial for optimising trial design and interpretation of results. 💡Implications for Trial Design: The findings underscore the need for thoughtful consideration of role assignments in trial design. Tailoring roles to maximise patient engagement and minimise bias can enhance the reliability and validity of PROs, ultimately strengthening the integrity of clinical trial data. 💡Enhancing Patient-Centricity: By recognising the impact of role assignments on PROs, trial sponsors can prioritise patient-centric approaches that prioritise patient well-being and participation. This fosters a more inclusive and collaborative clinical trial environment. By addressing he nuanced relationship between assigned roles and patient-reported outcomes in clinical trials thoughtfully, researchers can enhance the quality and relevance of trial results, ultimately benefiting patients and advancing medical science. Read the full article here: https://bit.ly/3WTDT2o #ClinicalTrialRoles #PatientReportedOutcomes #TrialDesign #PatientCentricity

We're not just here to fill positions and collect fees – we're here to build lasting partnerships rooted in genuine care and support. Our commitment to ethical recruitment practices extends beyond business transactions; it's a reflection of our core values and dedication to making a positive impact in the world. That's why you'll find us here, actively engaging and providing valuable insights to help improve medicine and enhance the lives of patients. Get in touch today: https://lnkd.in/g_z8FmWD #GoodlandPharma #LifeScience #ClinicalTrials #RecruitmentPartnership

In a recent article by Cytel, the indispensable role of Key Opinion Leaders (KOLs) in the realm of rare disease clinical trials is illuminated. Rare diseases present unique challenges in drug development, from limited patient populations to complex regulatory pathways. Here are some key takeaways: 1. Expert Guidance: KOLs, with their deep expertise and insights, play a pivotal role in guiding clinical trial design and execution in the context of rare diseases. Their involvement ensures that trials are tailored to address the specific needs and challenges of these conditions. 2. Patient Advocacy: Beyond their scientific acumen, KOLs often serve as advocates for patients with rare diseases. Their advocacy can influence trial protocols, ensure patient-centric approaches, and ultimately improve the chances of success in clinical development. 3. Navigating Regulatory Hurdles: Regulatory bodies have unique considerations for rare disease therapies. KOLs, well-versed in both scientific advancements and regulatory landscapes, can help navigate these complexities, accelerating the path to regulatory approval. 4. Collaborative Networks: Establishing collaborative networks involving KOLs, researchers, industry stakeholders, and patient communities fosters a synergistic approach to tackling rare diseases. Such partnerships facilitate knowledge exchange, resource sharing, and innovative solutions. The collaboration between pharmaceutical companies and Key Opinion Leaders is paramount in advancing rare disease therapies. Their expertise, advocacy, and collaborative efforts are instrumental in overcoming the challenges inherent in rare disease clinical trials. Read the full insightful article here: https://bit.ly/44Y1jWi #RareDisease #ClinicalTrials #KeyOpinionLeaders #PatientAdvocacy

In an industry often tarnished by those chasing quick profits, Goodland Pharma stands out as a beacon of integrity and trustworthiness. Unlike others solely focused on the bottom line, our mission is clear: to achieve success through earning trust and making a meaningful difference. With Goodland Pharma, you’ll be joining forces with a team driven by a shared purpose: to improve medicine and uplift communities. Contact us today: https://lnkd.in/g_z8FmWD #GoodlandPharma #LifeScience #ClinicalTrials #RecruitmentPartnership

Team stability: A key ingredient in clinical trial success. Ensuring smooth sailing in clinical trials isn't just about protocols and procedures—it's about the people behind the scenes 💪🏻 Check out this insightful article on the vital role of team stability in advancing clinical trials by Atlantic Research Group. From fostering collaboration to maintaining consistency, learn why a stable team is the cornerstone of successful trials. Dive into the full article here: https://bit.ly/4bUnBdT #ClinicalTrials #TeamStability #ResearchExcellence #HealthcareInnovation

With a team comprised of industry experts and seasoned professionals, we offer unparalleled specialist knowledge that goes beyond the surface. Whether it's understanding the latest trends, navigating complex regulations, or identifying niche talent, we have the expertise to guide you every step of the way. Experience the difference of working with a trusted advisor who prioritises your success above all else. Get started here: https://lnkd.in/g_z8FmWD #GoodlandPharma #ClinicalTrials #TalentSolutions #RecruitmentPartnership